Sunday - November 15, 2026
Bayer's SUNHARBO(r) (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination
November 09, 2026
WHIPPANY, New Jersey, Nov. 9 [Category: BizPharmaceuticals] -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, posted the following news:

* * *

Bayer's SUNHARBO(r) (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplat . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products